Could an extremely rare hormonal condition be quietly fueling a global pharmaceutical race? Once confined to textbooks and obscure endocrinology journals, acromegaly is now driving new interest in breakthrough treatments and biotech innovation. With symptoms that go unnoticed for years, patients around the world are finally getting earlier diagnoses—and pharma companies are racing to meet...